Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2011
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
M D Galsky, G J Chen, W K Oh, et al.
British Journal of Cancer
|
June 6, 2013
Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
M D Kaymakcalan, Y Je, G Sonpavde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2013
Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors
T K Choueiri, Y Je, G Sonpavde, et al.
ESMO Open
|
February 26, 2026
Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial
J Bedke, M S van der Heijden, G Sonpavde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2009
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
G Sonpavde, P O Periman, D Bernold, et al.
Urologic Oncology
|
June 24, 2021
An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer
K Montazeri, G Dranitsaris, J D Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
A J Armstrong, P Lin, C S Higano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2014
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials
R J van Soest, A J Templeton, F E Vera-Badillo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2011
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
G Sonpavde, V Matveev, J M Burke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 10, 2011
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
J S de Bono, L R Molife, G Sonpavde, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2011
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
M D Galsky, G J Chen, W K Oh, et al.
British Journal of Cancer
|
June 6, 2013
Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
M D Kaymakcalan, Y Je, G Sonpavde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2013
Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors
T K Choueiri, Y Je, G Sonpavde, et al.
ESMO Open
|
February 26, 2026
Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial
J Bedke, M S van der Heijden, G Sonpavde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 28, 2009
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
G Sonpavde, P O Periman, D Bernold, et al.
Urologic Oncology
|
June 24, 2021
An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer
K Montazeri, G Dranitsaris, J D Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
A J Armstrong, P Lin, C S Higano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2014
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials
R J van Soest, A J Templeton, F E Vera-Badillo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2011
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
G Sonpavde, V Matveev, J M Burke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 10, 2011
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
J S de Bono, L R Molife, G Sonpavde, et al.
Page
of 3